Erwin S1 1 augustus 2025 10:41 auteur info Erwin S1 Lid sinds: 07 nov 2023 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 85 Gegeven: 5 Aantal posts: 264 quote:4finance schreef op 31 juli 2025 21:16:BAYER, benieuwd wat de koers 2e helft van het jaar gaat doen. Je zou verwachten dat men in de USA ook wel een keer van de rechtszaken af wil en de boel wil schikken.Ja dat lijkt mij ook. Ik zit er al jaren in en steeds de hoop dat het een keer wordt opgelost. Dan spuit koers omhoog, ook omdat er dan veel pensioenmij weer mogen instappen Ik heb mijn GAK kunnen verlagen maar pas rond 40.00 break even (los van dividend) Met inflatie erbij moet het naar 50 Aanbevelingen 0 ” Quote Reageren Niet oké
LL 1 augustus 2025 13:54 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Bayer positiever gestemd over 202512:32 01/08/2025(ABM FN-Dow Jones) Bayer heeft meer vertrouwen gekregen in 2025. Dit bleek vrijdag uit voorlopige cijfers die het Duitse concern publiceerde.Bayer stelde de outlook voor de omzet en de winst, aangepast voor wisselkoerseffecten, naar boven bij.Voor de omzet wordt inmiddels gerekend op een jaaromzet van 46 tot 48 miljard euro, waar eerder werd uitgegaan van 45 tot 47 miljard euro.Voor de farmaceutische tak verwacht Bayer nu dat de omzet met 0 tot 3 procent zal groeien, gecorrigeerd voor valuta en andere factoren, ten opzichte van de eerdere prognose van een daling van 1 tot 4 procent.De omzetgroei van de divisie Consumer Health zal naar verwachting aan de onderkant van de eerdere bandbreedte van 2 tot 5 procent uitkomen.Voor de kernwinst per aandeel gaat Bayer nu uit van 4,80 tot 5,30 euro in plaats van 4,50 tot 5,00 euro.Op 6 augustus volgen de cijfers van Bayer over het tweede kwartaal.Het aandeel Bayer steeg vrijdag met 5,1 procent Aanbevelingen 0 ” Quote Reageren Niet oké
LL 6 augustus 2025 07:59 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Cijferswww.bayer.com/sites/default/files/202... Aanbevelingen 0 ” Quote Reageren Niet oké
LL 6 augustus 2025 08:40 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 BRIEF-Bayer CEO: Everything Remains On Table Regarding Glyphosate07:44 06/08/2025AFFIRM OUR OBJECTIVE TO SIGNIFICANTLY CONTAIN LITIGATION RISK BY END OF 2026AS PREVIOUSLY REPORTED, BAYER RECOGNIZED APPROXIMATELY 1.2 BILLION EUROS IN ADDITIONAL PROVISIONS FOR GLYPHOSATEAND APPROXIMATELY 530 MILLION EUROS IN PROVISIONS AND LIABILITIES FOR PCBS IN Q2IN ADDITION, WE'VE RECENTLY TAKEN THOUSANDS OF CASES OFF TABLE THROUGH CONFIDENTIAL SETTLEMENTS ON A LOW COST-PER-CASE AVERAGE IN GLYPHOSATE LITIGATIONSAYS EBITDA BEFORE SPECIAL ITEMS AT CROP SCIENCE INCREASED BY 32.3 PERCENT TO 693 MILLION EUROS, LARGELY THANKS TO VOLUME PHASING FROM PREVIOUS QUARTER IN CORN SEED BUSINESS AS WELL AS LOWER COSTSBAYER'S STRATEGY TO TACKLE GLYPHOSATE LITIGATION IS NOT SOLELY DEPENDENT ON A POSITIVE DECISION BY SUPREME COURTBROADER TIMELINE OF HAVING SUCH A SUPREME COURT RULING ON GLYPHOSATE BY SUMMER OF NEXT YEAR REMAINS INTACTEVERYTHING REMAINS ON TABLE REGARDING GLYPHOSATE Aanbevelingen 0 ” Quote Reageren Niet oké
LL 6 augustus 2025 08:41 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Bayer says it has cut 12,000 jobs so far under restructuring push08:17 06/08/2025FRANKFURT, Aug 6 (Reuters) - Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.Bayer, which is burdened by U.S. lawsuits claiming that its Roundup weedkiller causes cancer, has said it is holding off on breaking up the diversified group amid calls by some investors to sell the group's consumer health unit or separately list its crop science division on the stock market.A previous tally for jobs slashed in 2024 was at 7,000.The number of global employees as per end of June stood at close to 90,000, when counted in full-time equivalents, according to its quarterly report.The German maker of pharmaceuticals and crop protection products, which last week published preliminary results, also said in a statement that its financial provisions for Roundup litigation totalled $7.4 billion, or 6.3 billion euros.Bayer said last week it had set aside an additional 1.2 billion euros ($1.37 billion) in provisions for ongoing litigation in the United States over the Roundup weedkiller. Aanbevelingen 0 ” Quote Reageren Niet oké
LL 18 augustus 2025 15:46 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Bayer settles Sky Valley cases over chemical PCB15:18 18/08/2025Aug 18 (Reuters) - Bayer said on Monday it reached agreements in principle with more than 200 plaintiffs to resolve the so-called Sky Valley Education Center product liability cases related to the chemical PCB, but said payments were already reflected in recent financial reporting.Bayer said in its statement that the terms of the agreements of its Monsanto unit over environmental pollution with PCB, short for polychlorinated biphenyls, were confidential and subject to approval of final settlement agreements by the parties.The cost of the additional settlements was covered by the PCB litigation provision taken in the second quarter, it added.Bayer shares extended gains after the news and were up 2.7% by 1305 GMT, reaching a two-week high.Previous adverse verdicts in the litigation linked to the Sky Valley Education Center near Seattle were not covered by the deal and remain on appeal, Bayer added.A jury in the state of Washington in January ordered Bayer to pay $100 million to four people who said they contracted various health problems from PCB at the school, but found the company was not liable for injuries alleged by 11 others.Plaintiffs have said their health problems were due to PCBs leaking from the school's light fixtures. The chemicals were made by Monsanto, which Bayer acquired in 2018 for $63 billion.Since that acquisition, lawsuits over PCBs, and more significantly over claims that the weedkiller Roundup caused cancer, have weighed heavily on the company's shares.PCBs were once used widely to insulate electrical equipment, and were also used in such products as carbonless copy paper, caulking, floor finish and paint. They were outlawed by the U.S. government in 1979 after being linked to cancer and other health problems. Monsanto produced PCBs from 1935 to 1977.Bayer said in July it had set aside an additional 1.7 billion euros ($2 billion) in provisions and liabilities for U.S. litigation, about 1.2 billion euros of which were related to Roundup.($1 = 0.8568 euros)(Reporting by Ludwig Burger; Editing by Rachel More and Emelia Sithole-Matarise)((ludwig.burger@thomsonreuters.com;)) Aanbevelingen 0 ” Quote Reageren Niet oké
LL 27 augustus 2025 09:07 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Bayer AG's New Drug Application for Gadoquatrane Accepted for Review by U.S. FDA for Contrast-Enhanced MRI Use08:33 27/08/2025Bayer AG has announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational contrast agent, gadoquatrane, for review. This agent is intended for use in contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system and other body regions in both adults and pediatric patients, including neonates. If approved, gadoquatrane will become the lowest dose macrocyclic gadolinium-based contrast agent (GBCA) available in the U.S., with a dose of 0.04 mmol gadolinium per kilogram body weight, marking a 60 percent reduction compared to current macrocyclic GBCAs. The NDA submission is supported by positive data from Phase III QUANTI studies and is part of Bayer's efforts to offer safer imaging solutions amid rising cases of chronic diseases requiring frequent imaging. Regulatory reviews are also underway in Japan, the European Union, and other countries, with further applications planned worldwide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on August 27, 2025, and is solely responsible for the information contained therein.(C) Copyright 2025 - Public Technologies (PUBT) Aanbevelingen 0 ” Quote Reageren Niet oké
LL 22 september 2025 12:12 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 Bayer moves Parkinson's cell therapy into Phase III trial12:00 22/09/2025Trial results could underpin request for regulatory approvalBayer already working on manufacturing networkSeveral other research teams working on similar treatmentsBy Patricia WeissSAN SEBASTIAN, Spain, Sept 22 (Reuters) - Bayer has started the third phase of human testing of an experimental stem cell therapy for Parkinson's disease, with future results potentially underpinning a request for regulatory approval, the company said on Monday.Despite still being years from market launch, Bayer, which spent about $250 million on a new facility for cell therapies in California in 2023, said it is already working on a manufacturing network for the cell-replacement therapy.The cell and gene therapy push has been seen by investors as an uncertain longer-term attempt to revive its drug development pipeline while it seeks to reduce financial debt and fight litigation that could cost it billions of dollars.COMPETING CELL THERAPIES FOR PARKINSON'S DISEASEOver the near term, Bayer's pharmaceutical unit is banking on revenue from products such as new prostate cancer drug Nubeqa, kidney treatment Kerendia and a menopause relief drug to offset expiring patents for bestsellers like stroke prevention drug Xarelto and an older version of eye medication Eylea.The experimental Parkinson's therapy, developed by Bayer's BlueRock subsidiary, was previously shown to be well-tolerated, and the transplanted cells have grown as intended in patients' brains.Bayer's Asklepios Biopharmaceutical unit, also known as AskBio, is separately in Phase II of testing a new gene therapy for Parkinson's disease.The hunt for Parkinson's treatments has seen many setbacks over the past decades. But a number of research teams have said they are working on a similar approach that transplants modified cells to restore parts of the brain that normally produce dopamine.They include Japan's Sumitomo Pharma <4506.T>, a team at Lund University and Cambridge University, U.S. biotech firm Aspen Neuroscience, and a team at hospital network Mass General Brigham in Boston.For BlueRock's procedure, researchers take human stem cells and transform them into dopamine-producing nerve cells.When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease.There is currently no cure for Parkinson's disease, which causes progressive brain damage and affects more than 10 million people worldwide. Common symptoms are loss of muscle control, tremors, muscle rigidity and slowness of movement with dementia seen in some patients.(Reporting by Patricia Weiss; Writing by Ludwig Burger; Editing by Joe Bavier)((ludwig.burger@thomsonreuters.com;))Keywords: BAYER PARKINSONS/ (PIX) Aanbevelingen 0 ” Quote Reageren Niet oké
LL 27 oktober 2025 08:08 auteur info LL Lid sinds: 09 jan 2003 Laatste bezoek: 06 nov 2025 Aanbevelingen Ontvangen: 4913 Gegeven: 2778 Aantal posts: 7.724 UPDATE 2-US FDA approves Bayer's menopause relief drug19:50 24/10/2025Oct 24 (Reuters) - The U.S. Food and Drug Administration has approved Bayer's drug to ease hot flashes in menopausal women, the German company said on Friday, a welcome development following the regulator's three-month review extension.The drug, branded as Lynkuet, is a non-hormonal treatment designed to relieve moderate-to-severe vasomotor symptoms, also known as hot flashes, associated with menopause.Bayer said Lynkuet, a once-daily capsule to be taken at bedtime, is expected to be available in the U.S. beginning November.The drug's wholesale cost is $625 for a month's supply, though patient costs vary based on insurance, the company said. It has partnered with online pharmacy BlinkRx, through which eligible patients may pay as little as $25 a month via the Lynkuet Access, Savings and Support program.The FDA's approval for Lynkuet was based on three late-stage studies that showed the drug reduced the frequency and severity of hot flashes and eased sleep disturbances in menopausal women.Bayer has been gearing up to launch the drug this year, projecting annual peak sales of at least $1 billion, a strategic move to bolster its pharmaceuticals business amid mounting debt pressures.Its label, however, warns about possible drowsiness, increases in liver enzymes, risk of pregnancy loss, and seizures in people with a seizure history. Patients are advised to avoid grapefruit during treatment, Bayer said.The drug is already approved in Australia, Canada, the UK and Switzerland. An application is pending in the European Union.Japanese drugmaker Astellas' <4503.T> non-hormonal, oral treatment Veozah is the other approved treatment in the U.S. for hot flashes associated with menopause.(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)((Padmanabhan.Ananthan@thomsonreuters.com;))Keywords: HEALTH USA/BAYER (UPDATE 2) Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.